ArticleOpen forum infectious diseases2022
High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).
Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- High exposure of pregnant women to SARS-CoV-2 during COVID-19 waves in Senegal.BMC pregnancy and childbirth · 2026Article
- Assessing SARS-CoV-2 transmission in African households from the reanalysis of serosurveys.American journal of epidemiology · 2026Article
- Sentinel surveillance of COVID-19 in 2024-2025 shows the persistence of Omicron circulation and the introduction of the XFJ recombinant in the Republic of Guinea.The Pan African medical journal · 2026Article
- Seroprevalence Trends of Antibodies to SARS-CoV-2 in South Korea, 2021-2022: A Repeated Cross-Sectional Study.Influenza and other respiratory viruses · 2025Article
- SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa.AIDS (London, England) · 2025Article
- Snapshot of Anti-SARS-CoV-2 IgG Antibodies in COVID-19 Recovered Patients in Guinea.Journal of clinical medicine · 2024Article
- SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024Article
- Seroprevalence of SARS-CoV-2 antibodies in Republic of Congo, February 2022.Epidemiology and infection · 2023Article
- Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.Open forum infectious diseases · 2023Article
- Article
- Population-based sero-epidemiological investigation of the dynamics of SARS-CoV-2 infections in the Greater Accra Region of Ghana.Scientific reports · 2022Article
- Reconsidering the COVID-19 vaccine strategy in West and Central Africa.Lancet (London, England) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted 3 successive seroprevalence surveys, 3 months apart, using multistage cluster sampling to measure the extent and dynamics of the severe acute respiratory syndrome coronavirus 2 epidemic in Conakry, the capital city of Guinea. Seroprevalence increased from 17.3% (95% CI, 12.4%-23.8%) in December 2020 during the first survey (S1) to 28.9% (95% CI, 25.6%-32.4%) in March/April 2021 (S2), then to 42.4% (95% CI, 39.5%-45.3%) in June 2021 (S3). This significant overall trend of increasing seroprevalence (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.